News
Ixazomib induces durable responses in hard-to-treat amyloidosis
Photo courtesy of ASH SAN FRANCISCO—The oral proteasome inhibitor ixazomib induces high-quality hematologic responses in patients with relapsed/...
News
Antibody shows activity in relapsed/refractory NHL
“It is encouraging to see results in an NHL study that selects a different target than CD20,” said Kristie Blum, MD, of The Ohio State University...
News
Combo may enhance spleen reductions in MF
the 2014 ASH Annual Meeting SAN FRANCISCO—Combination therapy with ruxolitinib and panobinostat shows signs of efficacy in myelofibrosis (MF),...
News
Brentuximab tops chemo in HL, doc says
NEW YORK—Brentuximab vendotin—not conventional chemotherapy—is the second-line regimen of choice for recurrent Hodgkin lymphoma (HL) patients...
News
Speaker advocates chemo-based salvage in HL
Credit: Rhoda Baer NEW YORK—Physicians should use chemotherapy-based approaches—not brentuximab vedotin—as second-line therapy for recurrent...
News
Ruxolitinib improves disease control in PV
©ASCO/Phil McCarten CHICAGO—The JAK1/2 inhibitor ruxolitinib may be a “valuable new treatment option” for patients with polycythemia vera (PV)...
News
Elderly males with DLBCL require increased rituximab dosing
©ASCO/Phil McCarten CHICAGO—Elderly males with non-Hodgkin lymphoma (NHL) may require one-third higher doses of rituximab than the current...
News
Switch to nilotinib improves deep molecular response in CML
©ASCO/Phil McCarten CHICAGO—Patients with chronic myeloid leukemia (CML) are more likely to achieve a deep molecular response if they switch to...
News
CAR T-cell therapy successfully used frontline as consolidation in CLL
©ASCO/Todd Buchanan CHICAGO—Infusion of autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells appears to have promising anti-...
News
Lenalidomide combination improves QOL in newly diagnosed MM
©ASCO/Scott Morgan CHICAGO—Substituting lenalidomide for thalidomide in the standard treatment of newly diagnosed multiple myeloma (MM) improves...
News
Novel agent shows promising activity in heavily pretreated NHL
©ASCO/Rodney White CHICAGO—The novel, oral selective inhibitor of nuclear transport known as selinexor (KPT-330) can safely be given as...
News
JAK inhibitor ruxolitinib improves treatment landscape in MF
CHICAGO—Two phase 3 studies demonstrate the effectiveness of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in treating...
News
Fostamatinib successfully targets the B-cell receptor
The B-cell receptor is present on both normal B cells and malignant B cells. Signaling through this receptor is necessary for B-cell maturation...